Drug study will use synthetic cannabidiol to fight antimicrobial resistance
Addressing antimicrobial resistance is a pressing priority for the largest health agencies in the world, so Botanix is optimistic in its efforts to proactively navigate these challenges.
Recruitment has today commenced in Perth for a Phase 2a study of Botanix’s antimicrobial platform product BTX 1801 to evaluate its safety, tolerability and efficacy for the prevention of surgical site infections.
The Phase 2a clinical study has been designed to evaluate two formulations of BTX 1801 to decolonise Staphylococcus aureus (Staph) and methicillin-resistant Staphylococcus aureus (MRSA or ‘Golden Staph’) from the nose of healthy adults. Nasal carriage of Staph and/or MRSA greatly increases the risks of serious and sometimes life-threatening infections following surgery, as patients essentially infect themselves.
Botanix is working with a team of specialist clinical investigators, led by Murdoch University’s Chair of Public Health and Chair of the Australia Group on Antimicrobial Resistance, Professor Geoffrey Coombs.
Read the Murdoch University news article here.
